NCT00811733View on ClinicalTrials.gov

A Phase II Trial of Ofatumumab in Subjects With Waldenstrom's Macroglobulinemia

PHASE2CompletedINTERVENTIONAL
Enrollment

37

Participants

Timeline

Start Date

March 1, 2009

Primary Completion Date

June 1, 2011

Study Completion Date

February 1, 2014

Conditions
Waldenstrom Macroglobulinaemia
Interventions
BIOLOGICAL

Ofatumumab

Ofatumumab is a fully human antibody, targeting a unique epitope on the CD20 molecule expressed on human B cells.

Trial Locations (7)

10021

GSK Investigational Site, New York

14263

GSK Investigational Site, Buffalo

55905

GSK Investigational Site, Rochester

78229

GSK Investigational Site, San Antonio

94305

GSK Investigational Site, Stanford

90095-6984

GSK Investigational Site, Los Angeles

43210-1228

GSK Investigational Site, Columbus

Sponsors

Lead Sponsor

GlaxoSmithKline
All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY

NCT00811733 - A Phase II Trial of Ofatumumab in Subjects With Waldenstrom's Macroglobulinemia | Biotech Hunter | Biotech Hunter